Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (61-70 of 229) with videos related to

Pageof 23
Sort By:
Archives of Internal Medicine|January 16, 2008
Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseAndrew Briggs, Michael Spencer, Hong Wang, et al.
Pharmacoeconomics|November 27, 2022
Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information AnalysesNichola R Naylor, Jack Williams, Nathan Green, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2024
Reporting Uncertainty Around Health-State Values: A Standard Method and Worked ExampleNancy J Devlin, Giselle Abangma, Andrew Lloyd, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Pharmacoeconomics|July 28, 2018
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort ModelsAnthony J Hatswell, Ash Bullement, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
Health Economics|September 10, 2011
Spoilt for choice: implications of using alternative methods of costing hospital episode statisticsClaudia Geue, James Lewsey, Paula Lorgelly, et al.
Journal of the Royal Society of Medicine|August 24, 2023
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?Aris Angelis, Ajay Aggarwal, Alec Miners, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Applied Health Economics and Health Policy|February 11, 2005
The use of probabilistic decision models in technology assessment : the case of total hip replacementAndrew Briggs, Mark Sculpher, Jill Dawson, et al.
Pageof 23

Showing results (61-70 of 229) with videos related to

Sort By:
Pageof 23
Archives of Internal Medicine|January 16, 2008
Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary diseaseAndrew Briggs, Michael Spencer, Hong Wang, et al.
Pharmacoeconomics|November 27, 2022
Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information AnalysesNichola R Naylor, Jack Williams, Nathan Green, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 18, 2024
Reporting Uncertainty Around Health-State Values: A Standard Method and Worked ExampleNancy J Devlin, Giselle Abangma, Andrew Lloyd, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Pharmacoeconomics|July 28, 2018
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort ModelsAnthony J Hatswell, Ash Bullement, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
Health Economics|September 10, 2011
Spoilt for choice: implications of using alternative methods of costing hospital episode statisticsClaudia Geue, James Lewsey, Paula Lorgelly, et al.
Journal of the Royal Society of Medicine|August 24, 2023
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?Aris Angelis, Ajay Aggarwal, Alec Miners, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.
Applied Health Economics and Health Policy|February 11, 2005
The use of probabilistic decision models in technology assessment : the case of total hip replacementAndrew Briggs, Mark Sculpher, Jill Dawson, et al.
Pageof 23